RetinalGenix Technologies (RTGN) Share-based Compensation (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Share-based Compensation of $10000.0 for Q1 2026, down 95.69% on a YoY basis from $231933.0 in Q1 2025, and down 96.44% sequentially from $281246.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Share-based Compensation (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Share-based Compensation data on file, last reported at $10000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 95.69% year-over-year to $10000.0; the trailing twelve-month figure through Mar 2026 stood at $10000.0 (down 99.67% YoY), and the FY2025 full-year result was $1.0 million, down 60.13% from the prior year.
- Share-based Compensation fell to $10000.0 in Q1 2026, from $281246.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.3 million in Q4 2024 to a low of $10000.0 in Q1 2026.
- A 5-year average of $436279.8 and a median of $250189.0 in 2025 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation soared 2107.18% in 2024 and slumped 95.69% in 2026, its largest moves.
- Tracing RTGN's Share-based Compensation over 5 years: stood at $586370.0 in 2022, then decreased by 13.98% to $504386.0 in 2023, then soared by 349.82% to $2.3 million in 2024, then plunged by 87.6% to $281246.0 in 2025, then plunged by 96.44% to $10000.0 in 2026.
- Business Quant data shows RTGN's Share-based Compensation at $10000.0 in Q1 2026, $281246.0 in Q4 2025, and $277226.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 139.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 35.80 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 35.12 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 35.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 10,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 281,246.00 |
| Dec 31, 2025 | 281,246.00 |
| Sep 30, 2025 | 277,226.00 |
| Sep 30, 2025 | 277,226.00 |
| Jun 30, 2025 | 250,189.00 |
| Jun 30, 2025 | 250,189.00 |
| Mar 31, 2025 | 231,933.00 |
| Mar 31, 2025 | 231,933.00 |
| Dec 31, 2024 | 2.27 Mn |
| Dec 31, 2024 | 2.27 Mn |
| Sep 30, 2024 | 296,256.00 |
| Sep 30, 2024 | 296,256.00 |
| Jun 30, 2024 | 211,009.00 |
| Jun 30, 2024 | 211,009.00 |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 504,386.00 |
| Dec 31, 2023 | 504,386.00 |